Clearmind Medicine Featured in "Psychedelics Tonight," Streaming on ALTRD.TV
October 11, 2022 09:00 ET
|
Clearmind Medicine Inc.
The first episode, "Psychedelic Novelty - Before it was Cool," introduces the company's proprietary molecule MEAI VANCOUVER, Oct. 11, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (CSE: CMND),...
Clearmind Announces Notice of Proposed Stock Consolidation
September 25, 2022 09:36 ET
|
Clearmind Medicine Inc.
VANCOUVER, Sept. 25, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (CSE: CMND), (OTC Pink: CMNDF), (FSE: CWY0) (“Clearmind” or the "Company"), a biotech company focused on discovery and...
Clearmind Applies for Patent to Treat Obesity and Metabolic Syndrome
September 22, 2022 08:30 ET
|
Clearmind Medicine Inc.
Patent Application, Based on Research at the Hebrew University, is Latest Result of Ongoing Collaboration with SciSparc Ltd. VANCOUVER, Sept. 22, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine...
Clearmind Medicine Announces Share-Based Payment for one of the Company's Consultants
September 16, 2022 16:30 ET
|
Clearmind Medicine Inc.
VANCOUVER, Sept. 16, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (CSE: CMND), (OTC Pink: CMNDF), (FSE: CWY0) (“Clearmind” or the "Company"), a biotech company focused on discovery and...
Clearmind Medicine Announces Additional Positive Pre-Clinical Results for its Cocaine Addiction Treatment
August 24, 2022 10:24 ET
|
Clearmind Medicine Inc.
The dedicated treatment indicated a significant decrease in cocaine craving in a sub- group that received Clearmind's MEAI VANCOUVER, Aug. 24, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc....
Yale’s Department of Psychiatry Chair to Join Clearmind Medicine
June 21, 2022 09:00 ET
|
Clearmind Medicine Inc.
Dr. John H. Krystal, world-leading expert in alcoholism and depression, will serve on scientific advisory board VANCOUVER, June 21, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (CSE: CMND,...
Clearmind Medicine Appoints New Chief Financial Officer
June 15, 2022 16:52 ET
|
Clearmind Medicine Inc.
VANCOUVER, June 15, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (CSE: CMND, OTC Pink: CMNDF, FSE: CWY0) (“Clearmind” or the "Company"), a biotech company focused on discovery and development of...
Clearmind Medicine Announces Positive Pre-Clinical Results for Cocaine Addiction Treatment
June 07, 2022 08:30 ET
|
Clearmind Medicine Inc.
The dedicated treatment demonstrated a significant decrease in preference for an area associated with cocaine VANCOUVER, June 07, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine...
Clearmind Medicine and SciSparc Collaboration Yields Another Patent Application for Cocaine Addiction Treatment
June 02, 2022 07:48 ET
|
Clearmind Medicine Inc.
No dedicated treatment currently available for cocaine addiction VANCOUVER, June 02, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (CSE: CMND, OTC Pink: CMNDF, FSE: CWY0) (“Clearmind” or the...
Clearmind Medicine Granted Patent Approval for Psychedelic- Based Alcohol Substitute in India
June 01, 2022 08:11 ET
|
Clearmind Medicine Inc.
The patent was granted by India’s Office of the Controller-General of Patents, Designs and Trademarks VANCOUVER, June 01, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (CSE: CMND, OTC Pink:...